Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

37.60
-0.9300-2.41%
Post-market: 37.38-0.2249-0.60%19:51 EDT
Volume:1.78M
Turnover:67.11M
Market Cap:4.00B
PE:45.85
High:38.44
Open:38.09
Low:37.15
Close:38.53
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.43
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:6.17
PE(LYR):45.85

Loading ...

Corcept Therapeutics Inc - FDA Issues Complete Response Letter for Relacorilant Nda

THOMSON REUTERS
·
Dec 31, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM

Reuters
·
Dec 31, 2025

S&P 500 Futures Decline In Premarket Trading; Corcept Therapeutics, Hecla Mining Lag

Dow Jones
·
Dec 31, 2025

Insider Confidence In December 2025's Leading Growth Companies

Simply Wall St.
·
Dec 26, 2025

High Growth Companies With Strong Insider Confidence December 2025

Simply Wall St.
·
Dec 25, 2025

Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

Benzinga_recent_news
·
Dec 23, 2025

Corcept Therapeutics (CORT): Assessing Valuation After a Strong Year-to-Date Share Price Surge

Simply Wall St.
·
Dec 22, 2025

These Stock Funds Are Cruising. Their 2026 Picks. -- Barron's

Dow Jones
·
Dec 20, 2025

These Stock Funds Are Crushing the Market. Here Are Their Picks for 2026. -- Barrons.com

Dow Jones
·
Dec 19, 2025

Corcept's Hypercortisolism Sales Outlook Seen as Unrealistic -- Market Talk

Dow Jones
·
Dec 17, 2025

Oil Prices Sink To $55, Lowest In Nearly 5 Years: What's Moving Markets Tuesday?

Benzinga
·
Dec 17, 2025

UBS Initiates Corcept Therapeutics at Neutral With $95 Price Target

MT Newswires Live
·
Dec 16, 2025

Corcept Therapeutics Inc : UBS Initiates Coverage With Neutral Rating and Target Price $95

THOMSON REUTERS
·
Dec 16, 2025

Corcept Therapeutics Initiated at Neutral by UBS

Dow Jones
·
Dec 16, 2025

Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares

Reuters
·
Dec 04, 2025

Corcept Therapeutics (CORT): Assessing Valuation After Revenue Outlook Revision and Growth in Korlym Prescriptions

Simply Wall St.
·
Nov 29, 2025

Corcept Therapeutics Chief Development Officer William Guyer Reports Sale of Common Shares

Reuters
·
Nov 27, 2025

Corcept Therapeutics Price Target Maintained With a $145.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 25, 2025

Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares

Reuters
·
Nov 08, 2025

Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares

Reuters
·
Nov 06, 2025